Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 22, Issue 10, 1998, Pages 999-1003

  Gordon, B ^a   Tarantolo, S ^a   Ruby, E ^b   Stephens, L ^a   Lynch, J ^b   Kessinger, A ^a   Haire, W ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Multiple organ dysfunction; Syndrome; Thrombocytopenia; Transfusion; VOD

Indexed keywords

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

EID: 0031751222     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701464     Document Type: Article

References (34)

1. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
2. Rio B, Andreu G, Nicod A et al. Thrombocytopenia in venoocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67: 1773-1776.
3. McDonald GB, Hinds MS, Fisher LD, Schoch HG. Liver toxicity following cytoreductive therapy for marrow transplantation: risk factors, incidence and outcome. Hepatology 1991; 14: 162a.
4. Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81: 3458-3462.
5. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
6. Haire WD, Ruby EI, Gordon BG et al. Multiple organ dysfunction syndrome in bone marrow transplantation. J Am Med Assoc 1995; 274: 1289-1295.
7. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. Ann Surg 1985; 202: 685-693.
8. Heffner JE, Sahn SA, Repine JE. The role of platelets in the adult respiratory distress syndrome: culprits or bystanders? Am Rev Resp Dis 1987; 135: 482-492.
9. Grau GE, Lou J. TNF in vascular pathology: the importance of platelet-endothelium interactions. Res Immunol 1993; 144: 355-369.
10. Piguet PF, Vesin C, Ryser JE et al. An effector role of platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a GD11a- and CD54-dependent interaction with endothelium. Infect Immunol 1993; 61: 4182-4187.
11. Kessinger A, Armitage JO, Smith DM et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
12. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation. Diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
13. Jones RJ, Lee KS, Beschorner WE et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
14. Haire WD, Stephens LC, Kotulak GD et al. Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 1995; 15: 505-507.
15. Richard S, Seigneur M, Blann A et al. Vascular endothelial lesion in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 18: 955-959.
16. Testa S, Manna A, Porcellini A et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996; 18 : 383-388.
17. Holler E, Kolb HJ, Möller A et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
18. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
19. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ system failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992; 101: 816-823.
20. Hesselvik JF, Blomback M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relationship to outcome. Crit Care Med 1989; 17: 724-733.
21. Nedorn E, Wosegien F, Kemmler G. Antithrombin III and early prognosis in polytraumatized patients: a pilot study. Klinische Wochenschrift 1991; 69: 817.
22. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985; 66: 1105-1109.
23. Bishop JF, McGrath K, Wolf MM et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71: 383-387.
24. Hussein MA, Long T, Zuccaro K. Platelet transfusion recovery and survival in stable bone marrow transplant patients. A prospective study. Blood 1995; 86 (Suppl. 1): 103a.
25. Benson K, Fields K, Hiemenz J et al. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. Semin Oncol 1993; 20: 102-109.
26. Rabinowitz J, Petros WP, Reisner EG et al. Analysis of factors affecting platelet transfusion requirements following high dose chemotherapy and autologous bone marrow support (ABMS). Blood 1994; 84 (Suppl. 1): 492a.
27. Meade CJ, Heuer H, Kempe R. Biochemical pharmacology of platelet-activating factor (and PAF antagonists) in relation to clinical and experimental thrombocytopenia. Biochem Pharmacol 1991; 41: 657-668.
28. Ou MC, Kambayashi J, Kawasaki T et al. Potential etiologic role of PAF in two major septic complications: disseminated intravascular coagulation and multiple organ failure. Thromb Res 1994; 73: 227-238.
29. Dhainaut JF, Mira JP, Brunet F. Platelet-activating factor antagonists as therapeutic strategy in sepsis. Prog Clin Biol Res 1994; 388: 277-293.
30. Dickniete G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae-induced sepsis. Thromb Haemost 1993; 69: 98-102.
31. Phillips TF, Staricco A, Assarian GS et al. Antithrombin administration protects from experimental DIC. Blood 1983; 62 (Suppl. 1): 308a.
32. Haire WD, Stephens LC, Ruby EI. Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT): results of a pilot study. Blood 1996; 88 (Suppl. 1): 458a.
33. Morris J, Harris RE, Hashmi R et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878.
34. Fujimoto T, Suzuki H, Tanoue K et al. Cerebrovascular injuries induced by activation of platelets in vivo. Stroke 1985; 16: 245-250.